Annovis Bio Inc

NYSE:ANVSUnited States

Annovis Bio, Inc. is a clinical-stage drug platform company addressing neurodegeneration such as Alzheimer’s disease (AD), Parkinson’s disease (PD) and other chronic neurodegenerative diseases. The Company is developing its lead product candidate, Buntanetap, which is designed to address AD, PD, and potentially other chronic neurodegenerative diseases. Buntanetap is a synthetically produced small molecule, orally administered, brain penetrant compound. Its product candidate ANVS405 is an intravenous drug being developed for acute indications and focused on protecting the brain after traumatic brain injury (TBI) and/or stroke. ANVS405 is the same compound as Buntanetap, given in cases of acute head and brain trauma. ANVS301 is an orally administered drug being developed to increase cognitive capability in later stages of AD and dementia. ANVS301 is observed to improve memory and learning in very old rats by lowering the number of errors from six to three.

Contact Information

Headquarters

101 LINDENWOOD DRIVE, SUITE 225MALVERN, PA, United States 19355

Phone

484-875-3192

Fax

610-727-4001

Executives

Independent Chairman of the Board

Michael Hoffman

President, Chief Executive Officer, Founder, Interim Principal Financial Officer, Director

Maria Maccecchini

Independent Director

Claudine Bruck

Independent Director

Reid Mccarthy

Independent Director

Mark White